Pharmagreen Biotech Inc.

OTC: PHBI · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Coquitlam, BCCIK 0001435181Reports USD

#1 of 1,394 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 34

v0.1 · 5/100 weight · pillars only

↑ Piotroski F, listing tenure · ↓ balance-sheet leverage, return on assets

Methodology →

Revenue TTM

$4.3M

Rev growth YoY (TTM)

+144295.2%

Net income (FY)

-$875.5k

Employees

—

Market cap

$622.2k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$875.5k-$875.5k2022

Operating income-$1.1M-$1.1M2022

Total assets$209.0k$209.0k2022

Liabilities$2.0M$2.0M2022

Equity-$1.8M-$1.8M2022

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Pharmagreen Biotech Inc. earned -$875.5k in FY2022 net income.

Peers · Healthcare

Molecule Holdings Inc.——Stemsation International, Inc.——Concord Medical Services Holdings Limited58C ChitogenX Inc.——

Key facts

CEOPeter Wojcik

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersCoquitlam, BC

ExchangeOTC: PHBI

Employees—

IPO date2018-08-15

Latest filings

10-Q2023-08-14 10-Q2023-05-19 8-K2023-05-18 10-Q2023-02-14 10-K2023-01-17 8-K2022-12-02 10-Q2022-08-17 8-K2022-08-11

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.